BioSpace News Archive

The clinical-stage biopharma company celebrates its successful $22 million IPO

Karuna Therapeutics, Inc. (Nasdaq: KRTX), a clinical-stage biopharmaceutical company committed to developing novel therapies with the potential to transform the lives of people with disabling and potentially fatal neuropsychiatric disorders and pain, today announced that it has commenced an underwritten public offering of 2,600,000 shares of its common stock

Trevena, Inc. (Nasdaq: TRVN), a biopharmaceutical company focused on the development and commercialization of novel medicines for patients with central nervous system (CNS) disorders, today announced that Mark Demitrack, M.D., Senior Vice President and Chief Medical Officer, will present at the Stifel 2019 Healthcare Conference, sponsored by Stifel,

Liminal BioSciences Inc. announced that members of the management team will provide a business overview and update at the Jefferies 2019 London Healthcare Conference at 18:00 GMT on Wednesday, November 20, 2019 in London, UK.

Amarin Corporation plc (NASDAQ: AMRN), a pharmaceutical company focused on improving cardiovascular health, hosted a webcast today to discuss important data with study authors who presented at the American Heart Association 2019 Scientific Sessions, November 16-18.

Name change honors Tyson’s support for creating a new, nimble and diverse generation of tech-enabled physicians poised to be advocates for their patients and communities [18-November-2019] OAKLAND, Calif. , Nov. 18, 2019 /PRNewswire/ -- The Kaiser Permanente School of Medicine will be named in honor of late Kaiser Permanente Chairman and CEO Bernard J. Tyson , r

LabCorp® announced that it has priced its offering of $1,050,000,000 in senior notes.

Gladstone researchers Warner C. Greene and Eytan Herzig collaborated with Xyphos Biosciences, Inc., to develop a novel immunotherapy for HIV.

Arlington Capital Partners (“Arlington Capital”), a Washington, DC-based private equity firm, announced today that Quantum Spatial (“Quantum” or the “Company”) has executed a definitive agreement to be acquired by NV5 Global, Inc. (NASDAQ:NVEE) for $303 million

TriAltus Bioscience, LLC today announced the launch of its Activated Im7 affinity chromatography resin for the CL7/Im7 protein purification system